Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Kenneth F. Grossmann"'
Autor:
Montaser Shaheen, Jiayi Yu, Charles J. Link, Yousef Zakharia, Ramses F. Sadek, Robert R. McWilliams, Mohammed M. Milhem, Lucinda Tennant, Joseph J. Drabick, Olivier Rixe, Kenneth F. Grossmann, Gabriela R. Rossi, Nicholas N. Vahanian, Erik L. Brincks, Eugene P. Kennedy, Ravindra Kolhe, David H. Munn, Steven S. Shen, Christopher M Smith, Rafal Pacholczyk
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
BackgroundThe indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor immunity. Indoximod is a small-molecule IDO pathway inhibitor that reverses the immunosuppressive
Autor:
Benjamin Newell Voorhies, Jordan P. McPherson, Daniel S. Sageser, Siwen Hu-Lieskovan, Jocelyn Wallentine, Umang Swami, Kenneth F. Grossmann, Rebecca Pokorny, Zachary Tolman, Benjamin Haaland, Carolyn Luckett
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
BackgroundRandomized trials evaluating programmed cell death protein 1 (PD-1) inhibitors in metastatic melanoma either permitted treatment for 2 years (pembrolizumab) or more (nivolumab). The optimal duration of therapy is currently unknown due to li
Autor:
Gary C. Doolittle, Thach Giao Truong, Bryan A. Faller, James Moon, Robert M. Conry, Janice M. Mehnert, Adil Daud, Amy K. Harker-Murray, Dennis F. Moore, Michael J. Messino, Alain Algazi, Roger S. Lo, Antoni Ribas, Christopher D. Lao, Kenneth F. Grossmann, Joseph I. Clark, Kari Kendra, Rangaswamy Govindarajan, Luke Dreisbach, Megan Othus
Publikováno v:
Nat Med
Nature medicine, vol 26, iss 10
Nature medicine, vol 26, iss 10
Preclinical modeling suggests that intermittent BRAF inhibitor therapy may delay acquired resistance when blocking oncogenic BRAFV600 in melanoma1,2. We conducted S1320, a randomized, open-label, phase 2 clinical trial (NCT02196181) evaluating whethe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3928f445a7b302bd631e90a1c4fdbe25
https://europepmc.org/articles/PMC8063889/
https://europepmc.org/articles/PMC8063889/
Autor:
Pamela B. Cassidy, Levy Kopelovich, Chuan He Yang, Susan R. Pfeffer, Lawrence M. Pfeffer, Kenneth F. Grossmann, Sancy A. Leachman, Meiyun Fan
Publikováno v:
Journal of Clinical Medicine, Vol 4, Iss 12, Pp 2012-2027 (2015)
Journal of Clinical Medicine
Volume 4
Issue 12
Pages 2012-2027
Journal of Clinical Medicine; Volume 4; Issue 12; Pages: 2012-2027
Journal of Clinical Medicine
Volume 4
Issue 12
Pages 2012-2027
Journal of Clinical Medicine; Volume 4; Issue 12; Pages: 2012-2027
MicroRNAs (miRNAs) are a class of 22–25 nucleotide RNAs that control gene expression at the post-transcriptional level. MiRNAs have potential as cancer biomarkers. Melanoma is a highly aggressive form of skin cancer accounting for almost 4% of canc
Autor:
Neeraj Agarwal, Peg Esper, Sarah Scarlett, Joseph Merriman, David Gill, Wolfram E. Samlowski, Archana M. Agarwal, Stephanie Daignault, Katherine A. Skinner, Bruce G. Redman, Kinjal Parikh, Kenneth F. Grossmann, Alli M. Straubhar, Michael Toole, Ajjai Alva, Aaron M. Udager, David D. Stenehjem, Srinivas K. Tantravahi
Publikováno v:
Cancer immunology, immunotherapy : CII. 65(8)
In metastatic renal cell carcinoma (mRCC), survival benefit associated with objective response rates of 16–20 % with high-dose interleukin-2 (HDIL-2) is well established and discussed. Based on recently emerged data on efficacy of cancer immunother
Autor:
Kenneth F. Grossmann, Kim Margolin
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 7 (2015)
Historically, stage III–IV melanoma patients have had few options to achieve long-term survival. For patients with stage III disease, surgery alone may be curative for approximately 50%. Adjuvant treatment with a slightly greater impact on relapse-
Autor:
Hung T. Khong, Richard S. Ungerleider, Sanjiv S. Agarwala, Robert H.I. Andtbacka, Adil Daud, Kenneth F. Grossmann, Merrick I. Ross, John T. Vetto, Matthew H. Taylor, Maki Tanaka, Rogerio I. Neves
Publikováno v:
Journal of Clinical Oncology. 35:9510-9510
9510 Background: HF10 is a bioselected replication-competent oncolytic virus derived from HSV-1. Herein, we report the safety and efficacy data of HF10 + ipilimumab (ipi) combination treatment in a Phase II trial in melanoma. Methods: Key entry crite
Publikováno v:
Diagnostic cytopathology. 40(6)
Molecular testing of cancers to determine therapeutic eligibility is now standard of care and has changed the practice of pathology. Recent advances in the treatment of metastatic melanoma with BRAF and KIT inhibitors have increased the demand for mo
Autor:
Maki Tanaka, Richard S. Ungerleider, Robert L. Ferris, Kenneth F. Grossmann, Aislyn D. Boran, Robert H.I. Andtbacka, Hung T. Khong
Publikováno v:
Molecular Cancer Therapeutics. 14:C111-C111
Background: Here, we report on safety, recommended HF10 dose, viral shedding in body fluids and overall (all target lesions) and local (injected lesion) antitumor activity in patients (pts) with superficial tumors (13 squamous cell carcinoma, 9 malig
Autor:
Michael A. Postow, Kenneth F. Grossmann, Caroline Robert, Amy P. Abernethy, Isabelle Gilloteau, Paul Gagnier, Jason Chesney, Fiona Taylor, Homa Dastani, C. Coon
Publikováno v:
Journal of Clinical Oncology. 33:9029-9029
9029 Background: New therapies in advanced MEL improve survival, but QoL preservation is uncertain. NIVO (a PD-1 immune checkpoint inhibitor) and IPI are each approved as monotherapy for advanced M...